We are driven to develop meaningful therapies for patients while creating value for stockholders. We aim to develop patient-focused solutions by applying our innovative science and technologies with well-known pharmacology. We create innovative must-have medicines.
Press Release
January 24, 2023
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands Read More
November 29, 2022
Aspargo Extends Latin America Reach From Mexico To Argentina Read More
October 4, 2022
Aspargo’s Footprint Grows With Middle East Expansion Read More
June 21, 2022
Aspargo Expands Beyond Spain Into Latin America Read More
May 20, 2022
Aspargo Acquires Bandol® Sildenafil Spray Read More
September 29, 2020
Aspargo Acquires International Rights to Sildenafil Oral Spray Read More
May 4, 2020
Aspargo Announces Successful Completion of Pre-IND Meeting w/ FDA Read More